Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

NCT02467270 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT02467270
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02467270 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
Lead sponsor
Takeda
Phase
Phase 2
Overall status
Completed
Start date
July 13, 2015
Completion date
April 23, 2025
Enrollment
283 (actual)
Sites
86

Conditions

As the registry lists them; a condition with its own page is linked.

myeloid leukemia, chronic, chronic phase